Pathfinder Medical

Advancing endovascular procedures (Trading name for Stent Tek Ltd)

General Information
Industries
Biotechnology
Funding Stage
Series A
Product Stage
-
Business Model
-
Company Overview
Founded
2014
Employees
15
Location
London, United Kingdom
Pathfinder Medical - Company Details

Pathfinder Medical is a UK-based biotechnology startup that specializes in the development of innovative medical devices. Founded in 2014, the company has attracted notable attention in the industry, with its most recent achievement being a £8.50M Series A investment from a consortium of investors including Parkwalk Advisors, Deepbridge Capital, and Business Growth Fund in January 2022.

The company's flagship product is an electronic catheter guidance technology that facilitates advanced endovascular procedures. This groundbreaking technology aims to address a pressing clinical need, particularly in the context of conditions such as renal failure, peripheral arterial disease, and related complications arising from diabetes and high blood pressure.

The prevalence of renal failure and peripheral arterial disease underscores the urgent demand for more effective treatment options. With an estimated £1.6 billion yearly market for the applications of its technology, Pathfinder Medical is strategically positioned to make significant contributions to these critical areas of medical intervention.

Pathfinder Medical's innovative approach not only offers a more minimally invasive alternative to traditional open surgeries but also addresses the high failure rates associated with current procedures. By enabling clinicians to connect blood vessels in a minimally invasive manner, the company's technology has the potential to significantly improve patient outcomes while reducing healthcare costs related to repeat procedures and complications.

By leveraging the recent investment, Pathfinder Medical is poised to advance the development and commercialization of its technology, contributing to the evolution of endovascular procedures and significantly impacting the medical industry's approach to treating conditions such as renal failure and peripheral arterial disease.